Bladder Cancer (Treatment)

Halofuginone Inhibits Angiogenesis

Published in Cancer Weekly, October 11th, 1999

The antiangiogenic effect of halofuginone in bladder cancer by the inhibition of microvessel formation in vitro has been demonstrated in a recent study.

M. Elkin and colleagues at Israel's Hadassah-Hebrew University Hospital previously demonstrated that halofuginone, a widely-used alkaloid coccidiostat, is a potent inhibitor of collagen (alpha)1(I) and matrix metalloproteinase 2 gene expression. Halofuginone also suppresses extracellular matrix deposition and cell proliferation.

More recently, Elkin et al. investigated the effect of halofuginone on transplantable and chemically-induced mouse bladder carcinoma ("Inhibition of Bladder Carcinoma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-10-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry